Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov;24(11):1363-1368.
doi: 10.1111/ene.13395. Epub 2017 Aug 17.

GBA mutations in Parkinson disease: earlier death but similar neuropathological features

C H Adler  1 , T G Beach  2 , H A Shill  3 , J N Caviness  1 , E Driver-Dunckley  1 , M N Sabbagh  3 , A Patel  1 , L I Sue  2 , G Serrano  2 , S A Jacobson  4 , K Davis  4 , C M Belden  4 , B N Dugger  2   5 , S A Paciga  6 , A R Winslow  6 , W D Hirst  6 , J G Hentz  7
Affiliations

GBA mutations in Parkinson disease: earlier death but similar neuropathological features

C H Adler et al. Eur J Neurol. 2017 Nov.

Abstract

Background and purpose: Mutations in the glucocerebrosidase (GBA) gene are known to be a risk factor for Parkinson's disease (PD). Data on clinicopathological correlation are limited. The purpose of this study was to determine the clinicopathological findings that might distinguish PD cases with and without mutations in the GBA gene.

Methods: Data from the Arizona Study of Aging and Neurodegenerative Disorders were used to identify autopsied PD cases that did or did not have a GBA gene mutation. Clinical and neuropathological data were compared.

Results: Twelve PD cases had a GBA mutation and 102 did not. The GBA mutation cases died younger (76 vs. 81 years of age) but there was no difference in disease duration or clinical examination findings. No neuropathological differences were found in total or regional semi-quantitative scores for Lewy-type synucleinopathy, senile plaques, neurofibrillary tangles, white matter rarefaction or cerebral amyloid angiopathy scores.

Conclusions: In longitudinally assessed, autopsied PD cases, those with GBA mutations had a younger age at death but there was no evidence for clinical or neuropathological differences compared to cases without GBA mutations. Due to the small GBA group size, small differences cannot be excluded.

Keywords: Parkinson's disease; genetics; glucocerebrosidase; neuropathology.

PubMed Disclaimer

Conflict of interest statement

Financial disclosure/Conflict of Interest: The authors report no conflict of interest regarding the funding of this study.

References

    1. Sidransky E, Samaddar T, Tayebi N. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology. 2009;73:1424–1425. author reply 1425–1426. - PubMed
    1. Asselta R, Rimoldi V, Siri C, et al. Glucocerebrosidase mutations in primary parkinsonism. Park Relat Disord. 2014;20:1215–1220. - PMC - PubMed
    1. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain. 2009;132:1783–1794. - PMC - PubMed
    1. Balducci C, Pierguidi L, Persichetti E, et al. Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson’s disease. Mov Disord. 2007;22:1481–1484. - PubMed
    1. Murphy KE, Gysbers AM, Abbott SK, et al. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson’s disease. Brain. 2014;137:834–848. - PMC - PubMed

Substances